MedTrace Logo

Transitional Care Model Evaluation 2020

NCT04212962 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 962

Last updated 2023-03-16

No results posted yet for this study

Summary

The study is a randomized controlled trial to estimate the effects of the transitional care model (TCM) on hospital admissions and patients' experience during the year following the patient's qualifying discharge. The University of Pennsylvania, where TCM was developed, will be the coordinating center for the implementation. The study will be conducted in three large health systems spread throughout the U.S., drawing patients from seven hospitals in those systems. Eligible patients are older adults (age 65 and older) admitted to a participating hospital with symptoms of heart failure (HF), chronic obstructive pulmonary disease (COPD), or pneumonia (PNA). The evaluation will be conducted by Mathematica.

Conditions

Interventions

BEHAVIORAL

Transitional care model (TCM)

Patient education about post-discharge self-care and medications, arrangement of needed social services, coordination of information from medical providers interacting with patient

BEHAVIORAL

Usual care

usual hospital discharge and post-discharge care

Sponsors & Collaborators

  • University of Pennsylvania

    collaborator OTHER

  • Arnold Ventures

    collaborator UNKNOWN

  • Veterans Health Administration--St. Louis and Cleveland

    collaborator UNKNOWN

  • Trinity Health System

    collaborator INDUSTRY

  • Providence St. Joseph Health-Swedish Health Services (Swedish)

    collaborator UNKNOWN

  • University of California, San Francisco

    collaborator OTHER

  • Mathematica Policy Research, Inc.

    lead OTHER

Principal Investigators

  • Arkadipta Ghosh, PhD · Mathematica Policy Research, Inc.

  • Randall S Brown, PhD · Mathematica Policy Research, Inc.

Study Design

Allocation
RANDOMIZED
Purpose
HEALTH_SERVICES_RESEARCH
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-07-07
Primary Completion
2024-07-31
Completion
2025-02-28

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04212962 on ClinicalTrials.gov